Evolent Health (NYSE:EVH) was given a new $6.00 price target on by analysts at Piper Sandler.
Evolent Health (NYSE:EVH) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Evolent Health (NYSE:EVH) had its price target lowered by analysts at Citigroup Inc. from $11.50 to $9.50. They now have a "buy" rating on the stock.
Evolent Health, American Oncology Network Partner to Streamline Cancer Care [Yahoo! Finance]
Evolent Health (NYSE:EVH) had its price target lowered by analysts at JPMorgan Chase & Co. from $13.00 to $7.00. They now have an "overweight" rating on the stock.